Antibody response HIV Covid vaccine immunogenicity Antibody response SARS-CoV-2 AntiSARS-CoV vaccine HIV/AIDs CD4 level Surrogate virus neutralization test
Conditions
Interventions
CD4 level is lower or equal than 200 cells/mL.,CD4 level is more than 200 cells/mL.
Prevention,Prevention
Lower CD4 group,Higher CD4 group
Sponsors
Thai AIDS society
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Individuals living with HIV aged 18 years and above 2. on stable antiretroviral regimen for at least three months 3. Received at least two doses of the primary COVID-19 vaccine more than three months prior to enrollment in the study
Exclusion criteria
Exclusion criteria: 1. virologic failure, defined as an HIV viral load exceeding 200 copies/mL 2. high-level immunosuppression, such as the use of prednisolone at doses exceeding 20 mg/day methotrexate at doses exceeding 0.4 mg/kg/week, or previous administration of rituximab or TNF-alpha blockers within the past year 3. active autoimmune disease 4. contraindications for COVID-19 vaccination 5. previous administration of monoclonal antibodies, JAK inhibitors, or convalescent plasma for COVID-19 6. receipt of any other vaccination within 15 days prior to enrollment 7. self-reported history of SARS-CoV-2 infection in the 3 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AntiRBDIgG 1 month AU/mL | — |
Secondary
| Measure | Time frame |
|---|---|
| sVNT 1 month percent | — |
Countries
Thailand
Contacts
Public ContactNapon Hiranburana
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed